Sofosbuvir Tablets under the brand name of Hepcinat. Hepcinat (Sofosbuvir), a drug that has revolutionised the treatment of Chronic Hepatitis C virus (HCV) infection is made available at a very affordable price. HCV infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, and Ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects.
Sofosbuvir (SOF) is a potent first-in-class nucleotide inhibitor that acts directly on the viral replication enzyme and brings cure in as high as 90 to 100% of patients, which was never heard of in the treatment of HCV. The introduction of SOF, a safe and efficacious drug with the potential to cure HCV that affects 150-200 million people worldwide is indeed a rare event in the history of medicine. This is truly a momentous occasion for all those involved in the HCV care.